ClinicalTrials.gg
Not yet recruitingNCT07563920TBF-AMLUpdated May 4, 2026

TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission

An interventional study of Thiotepa and Busulfan (BU) in Acute Myeloid Leukemia, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Not yet recruiting. Open to participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
93
Allocation
Not applicable
Ages
55 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies testing thiotepa in Leukemia, Myeloid, Acute — 5 open to participants now, 7 under way, 1 of them phase 3. Thiotepa · Leukemia, Myeloid, Acute.

Planned enrollment
7th of 25
93 · median 41
Started
2026
with 2 others
No phase
2 of 25
1 open now
Registered
23rd of 25
by date

Among the 25 studies testing thiotepa in Leukemia, Myeloid, Acute, this one is the 7th largest by planned enrollment, is one of 3 that started in 2026, is one of 2 with no phase, and was the 23rd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

5 of the 25 studies testing thiotepa in Leukemia, Myeloid, Acute are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About thiotepa

Thiotepa: first FDA approval 1959 (THIOTEPA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 55 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing thiotepa in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Acute myeloid leukemia (AML) is a serious blood cancer that mainly affects older adults. For patients who achieve their first complete remission (CR1), allogeneic hematopoietic stem cell transplantation (HSCT) may provide a chance for long-term survival. However, relapse after transplantation remains a major challenge.

This study aims to evaluate the effectiveness and safety of a conditioning regimen that combines thiotepa, busulfan, and fludarabine (TBF) before haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) in elderly patients with AML in first complete remission.

Eligible patients will receive the TBF conditioning regimen followed by stem cell transplantation from a partially matched donor. Participants will be followed to assess relapse-free survival, overall survival, transplant-related complications, and infections.

The results of this study may help improve treatment strategies and outcomes for elderly AML patients undergoing transplantation.

Read the detailed description

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with increasing incidence in older populations. Despite achieving first complete remission (CR1) after induction chemotherapy, elderly patients remain at high risk of relapse and have poor long-term outcomes.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered a potentially curative treatment for AML. With the development of reduced-intensity conditioning regimens and haploidentical transplantation strategies, more elderly patients are now eligible for transplantation. However, relapse after transplantation remains a major limitation.

The conditioning regimen plays a critical role in determining transplant outcomes. The combination of thiotepa, busulfan, and fludarabine (TBF) has been proposed to enhance anti-leukemic activity while maintaining acceptable toxicity. Previous retrospective and registry-based studies suggest that TBF conditioning may reduce relapse risk compared with conventional regimens, but prospective data in elderly AML patients, especially in Asian populations, remain limited.

This study is a single-center, prospective, single-arm clinical trial designed to evaluate the efficacy and safety of the TBF conditioning regimen in elderly AML patients in first complete remission undergoing haploidentical peripheral blood stem cell transplantation (haplo-PBSCT).

Eligible patients aged 55-75 years with AML in CR1 or CRi will receive a conditioning regimen consisting of thiotepa (day -7), busulfan (days -4 and -3), and fludarabine (days -6 to -2), followed by infusion of donor stem cells on day 0.

The primary endpoint is 1-year relapse-free survival (RFS), defined as the time from transplantation to relapse or death from any cause. Secondary endpoints include overall survival, incidence of acute and chronic graft-versus-host disease (GVHD), non-relapse mortality, hematopoietic engraftment, donor chimerism, and infection rates.

Participants will be followed regularly after transplantation with clinical assessments, laboratory tests, and bone marrow evaluations according to protocol-defined schedules.

The findings from this study are expected to provide prospective evidence for the use of TBF conditioning in elderly AML patients and support optimization of transplantation strategies in this population.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Haploidentical Stem Cell Transplantation
  • TBF Conditioning Regimen
  • Thiotepa Busulfan Fludarabine
  • Elderly AML
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Relapse-Free Survival
04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 55 to 75 years
  • Diagnosed with acute myeloid leukemia (AML) based on morphology, immunophenotyping, cytogenetics, or molecular testing
  • First complete remission (CR1) or complete remission with incomplete hematologic recovery (CRi)
  • Eligible for haploidentical hematopoietic stem cell transplantation
  • Availability of a suitable haploidentical donor
  • performance status 0-2
  • Adequate organ function:

    • ≥50%
    • Oxygen saturation >92% on room air
    • Serum creatinine ≤1.5 × (ULN)
    • Total ≤1.5 × ULN
    • and ALT ≤2.0 × ULN
    • DLCO ≥40% and ≥50%
  • Ability to understand and sign

Exclusion criteria

Exclusion Criteria:

  • Secondary AML (including AML evolving from myelodysplastic syndrome or therapy-related AML)
  • Active, uncontrolled infection
  • Severe uncontrolled systemic disease (e.g., unstable cardiovascular disease, recent stroke, or severe organ dysfunction)
  • infection
  • Active or C requiring antiviral treatment
  • Pregnant or breastfeeding women
  • Known to study drugs
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
93 participants (estimated)

Study arms

  • Experimental
    Arms Back to Arms and Interventions * Required * § Required if Study Start Date is on or after Janu

    Participants will receive a conditioning regimen consisting of thiotepa, busulfan, and fludarabine (TBF) followed by haploidentical peripheral blood stem cell transplantation. Thiotepa is administered on day -7, busulfan on days -4 and -3, and fludarabine on days -6 to -2. Donor stem cells are infused on day 0. Standard graft-versus-host disease prophylaxis and supportive care will be provided according to institutional guidelines.

    Drug: Thiotepa · Drug: Busulfan (BU) · Drug: Fludarabine · Procedure: Haploidentical Peripheral Blood Stem Cell Transplantation

Interventions

  • Thiotepa is administered intravenously at a dose of 5 mg/kg on day -7 as part of the TBF conditioning regimen prior to haploidentical peripheral blood stem cell transplantation.

  • DrugBusulfanStudies of BusulfanBusulfan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Busulfan is administered intravenously at a dose of 3.2 mg/kg on days -4 and -3 as part of the TBF conditioning regimen.

  • Fludarabine is administered intravenously at a dose of 30 mg/m² daily from day -6 to day -2 as part of the conditioning regimen.

  • ProcedureHaploidentical Peripheral Blood Stem Cell Transplantation

    Haploidentical peripheral blood stem cell transplantation is performed on day 0 following conditioning. Donor stem cells are infused, and standard graft-versus-host disease prophylaxis and supportive care are provided according to institutional protocols.

06

What researchers measure

Primary outcomes

  1. 1-year Relapse-Free Survival (RFS)

    Relapse-free survival (RFS) is defined as the time from transplantation to the first occurrence of disease relapse or death from any cause. Patients who are alive without relapse at the last follow-up will be censored.

    Time frame: 12 months after transplantation

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from transplantation to death from any cause. Patients alive at last follow-up will be censored.

    Time frame: 12 months after transplantation

  2. Incidence of Acute Graft-Versus-Host Disease (aGVHD)

    The cumulative incidence of grade I-IV and grade III-IV acute graft-versus-host disease within 180 days after transplantation, assessed according to standard criteria.

    Time frame: Up to 180 days after transplantation

  3. Incidence of Chronic Graft-Versus-Host Disease (cGVHD)

    The cumulative incidence of all-grade and moderate-to-severe chronic graft-versus-host disease, assessed according to NIH consensus criteria.

    Time frame: 12 months after transplantation

  4. Non-Relapse Mortality (NRM)

    Non-relapse mortality is defined as death without evidence of disease relapse. Relapse is treated as a competing event.

    Time frame: 12 months after transplantation

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to patient privacy concerns and institutional data protection policies. De-identified data may be available from the corresponding investigator upon reasonable request and with appropriate institutional approvals.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2029, 36 months later.

Of 132 non-industry interventional studies with no phase under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 128. This study's planned 36 months is below that.

Counting every sponsor, half of 139 studies reached it within 47 months; a quarter within 25 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2026
First posted
May 4, 2026
StartEst.
Jun 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2030
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07563920
Responsible party
Xianmin Song, MD (Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
May 4, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jun 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
May 4, 2026

Study contacts

Xianmin Song, MD
Contact
shongxm@sjtu.edu.cn
+86-13501672508
Xianmin Song
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Thiotepa · Busulfan · Fludarabine

Start the discussion